Literature DB >> 28806268

Pharmacotherapy of eating disorders.

Haley Davis1, Evelyn Attia.   

Abstract

PURPOSE OF REVIEW: Medications are commonly prescribed in the treatment of eating disorders. In this review, we discuss relevant medications used for the treatment of bulimia nervosa, binge eating disorder (BED), and anorexia nervosa. We focus on recent research developments, where applicable, in addition to discussing important findings from older studies to provide a complete synopsis of the current evidence base for eating disorder treatment using pharmacologic agents. RECENT
FINDINGS: Medications are generally useful for patients with bulimia nervosa and BED. For bulimia nervosa, antidepressant medications are the primary pharmacologic treatment and limited new research has been completed. For BED, lisdexamfetamine is reported to be generally well tolerated and effective, and is the first medication to be indicated by the US Food and Drug Administration for treatment of BED. For anorexia nervosa, there is limited evidence supporting benefits of medications. Second-generation antipsychotics, particularly olanzapine, appear to demonstrate some benefit for weight gain in anorexia nervosa, although are not advised as a stand-alone treatment. Transdermal administration of hormonal agents is also being explored for improving bone health in anorexia nervosa.
SUMMARY: Although pharmacotherapy has established utility in bulimia nervosa and BED, further research on medications for the treatment of eating disorders, particularly anorexia nervosa, is necessary.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28806268      PMCID: PMC8221404          DOI: 10.1097/YCO.0000000000000358

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  55 in total

1.  A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder.

Authors:  Lesley M Arnold; Susan L McElroy; James I Hudson; Jeffrey A Welge; Aurora J Bennett; Paul E Keck
Journal:  J Clin Psychiatry       Date:  2002-11       Impact factor: 4.384

2.  Impact of physiologic estrogen replacement on anxiety symptoms, body shape perception, and eating attitudes in adolescent girls with anorexia nervosa: data from a randomized controlled trial.

Authors:  Madhusmita Misra; Debra K Katzman; Nara Mendes Estella; Kamryn T Eddy; Thomas Weigel; Mark A Goldstein; Karen K Miller; Anne Klibanski
Journal:  J Clin Psychiatry       Date:  2013-08       Impact factor: 4.384

3.  Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports.

Authors:  Mary Ellen Trunko; Terry A Schwartz; Vikas Duvvuri; Walter H Kaye
Journal:  Int J Eat Disord       Date:  2011-04       Impact factor: 4.861

4.  Long-term fracture risk among women with anorexia nervosa: a population-based cohort study.

Authors:  A R Lucas; L J Melton; C S Crowson; W M O'Fallon
Journal:  Mayo Clin Proc       Date:  1999-10       Impact factor: 7.616

5.  Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults.

Authors:  R Reife; G Pledger; S C Wu
Journal:  Epilepsia       Date:  2000       Impact factor: 5.864

6.  Treating bulimia with desipramine. A double-blind, placebo-controlled study.

Authors:  P L Hughes; L A Wells; C J Cunningham; D M Ilstrup
Journal:  Arch Gen Psychiatry       Date:  1986-02

7.  Bulimia treated with imipramine: a placebo-controlled, double-blind study.

Authors:  H G Pope; J I Hudson; J M Jonas; D Yurgelun-Todd
Journal:  Am J Psychiatry       Date:  1983-05       Impact factor: 18.112

8.  An open trial of fluoxetine for adolescents with bulimia nervosa.

Authors:  Lisa A Kotler; Michael J Devlin; Mark Davies; B Timothy Walsh
Journal:  J Child Adolesc Psychopharmacol       Date:  2003       Impact factor: 2.576

9.  A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.

Authors:  Maria Gasior; James Hudson; Javier Quintero; M Celeste Ferreira-Cornwell; Jana Radewonuk; Susan L McElroy
Journal:  J Clin Psychopharmacol       Date:  2017-06       Impact factor: 3.153

10.  Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.

Authors:  Susan L McElroy; James Hudson; M Celeste Ferreira-Cornwell; Jana Radewonuk; Timothy Whitaker; Maria Gasior
Journal:  Neuropsychopharmacology       Date:  2015-09-09       Impact factor: 7.853

View more
  11 in total

1.  Psychotropic usage by patients presenting to an academic eating disorders program.

Authors:  Karuna Mizusaki; Daniel Gih; Christina LaRosa; Rebekah Richmond; Renee D Rienecke
Journal:  Eat Weight Disord       Date:  2018-06-07       Impact factor: 4.652

Review 2.  Update on Treatments for Adolescent Bulimia Nervosa.

Authors:  Sasha Gorrell; Daniel Le Grange
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2019-07-04

Review 3.  A review of binge eating disorder and obesity.

Authors:  Zaida Agüera; María Lozano-Madrid; Núria Mallorquí-Bagué; Susana Jiménez-Murcia; José M Menchón; Fernando Fernández-Aranda
Journal:  Neuropsychiatr       Date:  2020-04-28

4.  Central Sensitization in Chronic Pain and Eating Disorders: A Potential Shared Pathogenesis.

Authors:  Leslie Sim; Cindy Harbeck Weber; Tracy Harrison; Carol Peterson
Journal:  J Clin Psychol Med Settings       Date:  2021-03

Review 5.  Psychopharmacologic Management of Eating Disorders.

Authors:  Alexandra F Muratore; Evelyn Attia
Journal:  Curr Psychiatry Rep       Date:  2022-05-16       Impact factor: 8.081

6.  Eating Disorders: An Evolutionary Psychoneuroimmunological Approach.

Authors:  Markus J Rantala; Severi Luoto; Tatjana Krama; Indrikis Krams
Journal:  Front Psychol       Date:  2019-10-29

7.  Effectiveness of integrated treatment for eating disorders in Spain: protocol for a multicentre, naturalistic, observational study.

Authors:  Antoni Grau Touriño; Guillem Feixas; Joan Carles Medina; Clara Paz; Chris Evans
Journal:  BMJ Open       Date:  2021-03-08       Impact factor: 2.692

8.  Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.

Authors:  Giovanni Martinotti; Stefania Chiappini; Mauro Pettorruso; Alessio Mosca; Andrea Miuli; Francesco Di Carlo; Giacomo D'Andrea; Roberta Collevecchio; Ilenia Di Muzio; Stefano L Sensi; Massimo Di Giannantonio
Journal:  Brain Sci       Date:  2021-06-27

9.  The Effects of the Monoamine Stabilizer (-)-OSU6162 on Binge-Like Eating and Cue-Controlled Food-Seeking Behavior in Rats.

Authors:  Kristin Feltmann; Chiara Giuliano; Barry J Everitt; Pia Steensland; Johan Alsiö
Journal:  Neuropsychopharmacology       Date:  2017-09-12       Impact factor: 7.853

10.  The monoamine stabilizer (-)-OSU6162 prevents the alcohol deprivation effect and improves motor impulsive behavior in rats.

Authors:  Ida Fredriksson; Malin Wirf; Pia Steensland
Journal:  Addict Biol       Date:  2018-02-26       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.